Adverum Biotechnologies, Inc. (LON:0HA3)
4.600
+0.309 (7.19%)
Inactive · Last trade price on Dec 9, 2025
Adverum Biotechnologies Revenue
In the year 2024, Adverum Biotechnologies had annual revenue of $1.00M USD, down -72.22%.
Revenue
$1.00M
Revenue Growth
-72.22%
P/S Ratio
n/a
Revenue / Employee
$6.45K
Employees
155
Market Cap
n/a
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.00M | -2.60M | -72.22% |
| Dec 31, 2023 | 3.60M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 7.50M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | 250.00K | -1.36M | -84.49% |
| Dec 31, 2018 | 1.61M | -237.00K | -12.82% |
| Dec 31, 2017 | 1.85M | 394.00K | 27.08% |
| Dec 31, 2016 | 1.46M | -864.00K | -37.26% |
| Dec 31, 2015 | 2.32M | 1.75M | 305.42% |
| Dec 31, 2014 | 572.00K | 92.00K | 19.17% |
| Dec 31, 2013 | 480.00K | 450.00K | 1,500.00% |
| Dec 31, 2012 | 30.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionAdverum Biotechnologies News
- 27 days ago - Thursday 12/11 Insider Buying Report: ADVM, ALTG - Nasdaq
- 4 weeks ago - Eli Lilly Moves Forward With Acquisition Of Adverum Biotechnologies - Nasdaq
- 4 weeks ago - Eli Lilly completes acquisition of Adverum Biotechnologies - Seeking Alpha
- 4 weeks ago - Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisition - PRNewsWire
- 4 weeks ago - Insider Buying: Laurent Fischer Acquires Shares of Adverum Biotechnologies Inc (ADVM) - GuruFocus
- 5 weeks ago - Eli Lilly (LLY) Sets Tender Offer to Acquire Adverum Biotechnologies - GuruFocus
- 5 weeks ago - Adverum Reminds Stockholders to Tender their Shares into the Offer by Lilly - GlobeNewsWire
- 7 weeks ago - The Zacks Analyst Blog Highlights Eli Lilly, Johnson & Johnson and Adverum - Nasdaq